First half orders up 19.9% to £201.5 million (2013: £168.0 million); on a constant currency organic basis, orders up 7.4%.
First half revenue up 7.3% to £178.5 million (2013: £166.3 million); on a constant currency organic basis revenues down 5.9%.
Adjusted operating profit of £18.9 million (2013: £22.0 million).
Adjusted EPS of 20.9 pence (2013: 28.6 pence).
Andor Technology acquisition integrating well and performing ahead of expectations; integration of RMG and RoentgenAnalytik acquisitions also proceeding to plan.
Investment in R&D up 41% to £18.3 million with sustained momentum in new product introductions and strong new product pipeline.
Interim dividend increased by 10.1% to 3.7 pence per share (2013: 3.36 pence).